You are here:

Reminyl XL®


Following an abbreviated submission.

New formulation of existing therapy.

Galantamine hydrobromide as Reminyl XLP®P prolonged-release capsules is accepted for use in NHS Scotland for the treatment of mild-to-moderately severe dementia in Alzheimer's disease in patients for whom therapy with galantamine is appropriate. It allows the reduction of dosing frequency to once daily and, at a given dose, involves no additional cost compared with immediate-release formulations of galantamine.

Drug Details

Drug Name: Reminyl XL®
SMC Drug ID: 139/04
Manufacturer: Shire Pharmaceuticals
Indication: Mild-to-moderately severe dementia in Alzheimer's disease
BNF Category:
Sub Category: 4.11 Drugs for dementia
Submission Type: Abbreviated Submission
Status: Superseded
Date Advice Published: 13 June 2005